Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

SSRI/SNRI Antidepressants Increase T2D Risk

JAMA Pediatr; ePub 2017 Oct 16; Brucu, et al

The most commonly used antidepressants increase the risk of type 2 diabetes (T2D) in youths, according to a cohort study of Medicaid recipients that included over 119,000 patients between the ages of 5 and 20 years. Among the findings:

  • Pediatric patients who were taking serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) were at increased risk of developing diabetes.
  • Patients were more likely to develop diabetes if they were current users of SSRIs and SNRIs, when compared to former users (absolute risk 1.29/10,000 person months vs 0.64/10,000 person months).
  • The risk of diabetes was also greater among patients using SSRIs/SNRIs when compared to tricyclic or other cyclic antidepressants.
  • Among patients currently using SSRIs/SNRIs, the risk of diabetes increased over time, with a relative risk of 2.66 when the drugs were used for >210 days, compared to 1 to 90 days duration.

Citation:

Burcu M, Zito JM, Safer DJ, et al. Association of antidepressant medications with incident type 2 diabetes among Medicaid-insured youths. [Published online ahead of print October 16, 2017]. JAMA Pediatr. doi:10.1001/jamapediatrics.2017.2896.